MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel. Show More...
-
Website https://www.mediwound.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 21.96 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.3 0.54 -0.75 -0.95 -1.02 -0.86 -0.95 -0.04 0.18 0.24 Dividends USD Payout Ratio % * Shares Mil 20.0 20.0 20.0 20.0 22.0 22.0 23.0 27.0 27.0 27.0 Book Value Per Share * USD 2.26 1.4 0.4 0.44 -0.07 0.67 0.47 Free Cash Flow Per Share * USD -0.72 -0.9 -0.82 -0.78 -0.78 0.29 Return on Assets % 43.01 -76.25 -43.92 -35.73 -42.78 -55.44 -2.66 13.06 18.2 Financial Leverage (Average) 1.63 1.66 2.24 4.6 4.59 3.93 2.68 2.93 Return on Equity % 69.98 -163.65 -66.59 -120.9 -254.73 -11.37 41.05 73.26 Return on Invested Capital % 66.56 -158.3 -64.91 -118.13 -249.24 -6.21 37.89 61.25 Interest Coverage -7.15 18.81 -2.48 -22.83 -24.68 -21.3 -16.57 -5.35 3.23 5.85 Current Ratio 0.97 5.96 17.58 9.68 6.25 7.64 6.68 3.43 3.08 Quick Ratio 0.64 5.71 17.16 9.31 6.05 7.27 6.31 3.24 2.89 Debt/Equity 0.13 0.15